Vincent Rajkumar

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Treatment of myeloma: cure vs control
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1142-5. 2008
  2. doi request reprint Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Hematol 88:226-35. 2013
  3. doi request reprint Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Hematology Am Soc Hematol Educ Program 2012:354-61. 2012
  4. ncbi request reprint Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation
    S V Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 68:269-75. 2001
  5. doi request reprint Front-line treatment in younger patients with multiple myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Hematol 46:118-26. 2009
  6. doi request reprint Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 26:2171-7. 2008
  7. ncbi request reprint Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation
    S Vincent Rajkumar
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 20:665-80. 2007
  8. ncbi request reprint Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
    Blood Rev 21:255-65. 2007
  9. ncbi request reprint Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:693-703. 2006
  10. ncbi request reprint Multiple myeloma: diagnosis and treatment
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1371-82. 2005

Research Grants

Detail Information

Publications97

  1. doi request reprint Treatment of myeloma: cure vs control
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1142-5. 2008
  2. doi request reprint Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Hematol 88:226-35. 2013
    ..Multiple myeloma accounts for approximately 10% of hematologic malignancies...
  3. doi request reprint Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Hematology Am Soc Hematol Educ Program 2012:354-61. 2012
    ....
  4. ncbi request reprint Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation
    S V Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 68:269-75. 2001
    ..It is also prognostic for poor survival and PFS following SCT for myeloma. We recommend that all three methods of estimating BMPC% be routinely performed and that the highest value be used for prognostic purposes...
  5. doi request reprint Front-line treatment in younger patients with multiple myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Hematol 46:118-26. 2009
    ..This review discusses the current status of front-line therapy in younger patients with myeloma who are candidates for stem cell transplantation...
  6. doi request reprint Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 26:2171-7. 2008
    ..The goal of this study was to compare thalidomide plus dexamethasone versus placebo plus dexamethasone (placebo/dex)as primary therapy for newly diagnosed MM...
  7. ncbi request reprint Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation
    S Vincent Rajkumar
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 20:665-80. 2007
    ....
  8. ncbi request reprint Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
    Blood Rev 21:255-65. 2007
    ..Updated diagnostic criteria for these disorders, risk-stratification models to determine prognosis, and the current management of these two entities are discussed in this review...
  9. ncbi request reprint Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:693-703. 2006
    ..Updated diagnostic criteria for these disorders, risk stratification models to determine prognosis, and the current management of these diverse entitles are discussed in this review...
  10. ncbi request reprint Multiple myeloma: diagnosis and treatment
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1371-82. 2005
    ..The current approach to the diagnosis, prognosis, and management of MM is reviewed...
  11. pmc Prevention of progression in monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 15:5606-8. 2009
    ..Because myeloma is an incurable malignancy, strategies to delay or prevent progression in high-risk patients are of considerable importance...
  12. pmc Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
    S Vincent Rajkumar
    Mayo Clinic, Rochester, Minnesota, USA
    Lancet Oncol 11:29-37. 2010
    ..High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We studied whether low-dose dexamethasone in combination with lenalidomide is non-inferior to and has lower toxicity than high-dose dexamethasone plus lenalidomide...
  13. ncbi request reprint Conventional therapy and approach to management
    S Vincent Rajkumar
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 18:585-601. 2005
    ..We also outline the role and current indications for the use of new active agents in this disease...
  14. ncbi request reprint A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies
    S Vincent Rajkumar
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Hematother Stem Cell Res 11:33-47. 2002
    ..Background information on pathogenesis and laboratory methods of quantifying bone marrow angiogenesis is also discussed...
  15. pmc Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic Rochester, Minnesota 55905, USA
    Am J Hematol 87:78-88. 2012
    ..Multiple myeloma accounts for ∼10% of all hematologic malignancies...
  16. pmc Approach to the treatment of multiple myeloma: a clash of philosophies
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Blood 118:3205-11. 2011
    ....
  17. pmc Treatment of multiple myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Nat Rev Clin Oncol 8:479-91. 2011
    ..A synthesized approach to the treatment of myeloma is presented, along with a discussion of key paradigms that need to be challenged...
  18. doi request reprint Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Hematol 86:57-65. 2011
    ..Multiple myeloma is malignant plasma-cell disorder that accounts for ∼10% of all hematologic malignancies...
  19. pmc Thromboembolic events with lenalidomide-based therapy for multiple myeloma
    Smitha Patiyil Menon
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 112:1522-8. 2008
    ..The purpose was to evaluate the incidence and risk factors of thromboembolism associated with lenalidomide therapy in newly diagnosed myeloma...
  20. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  21. pmc Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients
    John P Bida
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:685-93. 2009
    ..To systematically study the association of monoclonal gammopathy of undetermined significance (MGUS) with all diseases in a population-based cohort of 17,398 patients, all of whom were uniformly tested for the presence or absence of MGUS...
  22. ncbi request reprint Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 90:1650-4. 2005
    ..We present the first data on the outcome of patients with newly diagnosed multiple myeloma treated with Thal/Dex who did not undergo upfront ASCT...
  23. ncbi request reprint Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma
    Hans P Sviggum
    Mayo Medical School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Arch Dermatol 142:1298-302. 2006
    ....
  24. ncbi request reprint Prognostic value of angiogenesis in solitary bone plasmacytoma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1715-7. 2003
    ..02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma...
  25. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  26. ncbi request reprint Novel approaches to the management of myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 19:621-5. 2005
    ..These have shown significant clinical activity as single agents. Trials are ongoing to incorporate these new agents into the various stages of treatment and to combine them with other effective treatment modalities, including ASCT...
  27. ncbi request reprint Controversies regarding the use of dexamethasone in patients with multiple myeloma
    S Vincent Rajkumar
    Mayo Clinic, Rochester, MN, USA
    Clin Adv Hematol Oncol 6:103, 141. 2008
  28. ncbi request reprint Myeloma and the newly diagnosed patient: a focus on treatment and management
    S Vincent Rajkumar
    Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA
    Semin Oncol 29:5-10. 2002
    ..The role of supportive care strategies for patients with bone disease, such as the use of bisphosphonates, is also discussed...
  29. ncbi request reprint Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma
    Michael A Thompson
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Br J Haematol 123:305-8. 2003
    ..01; IL-6, 24% versus 70% at 2 years, P = 0.01). None of the other parameters predicted response or PFS, and no significant changes in cytokine levels occurred with therapy...
  30. doi request reprint Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
    Francesca Gay
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:664-9. 2010
    ..5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results...
  31. pmc Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:532-7. 2010
    ..This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents...
  32. pmc Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
    Grzegorz S Nowakowski
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 106:2276-9. 2005
    ..We conclude that the number of circulating PCs measured by flow cytometry in patients with newly diagnosed MM is an independent predictor of survival...
  33. ncbi request reprint Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Semin Hematol 40:17-22. 2003
    ..Phase III trials of thalidomide in newly diagnosed symptomatic multiple myeloma or smoldering/indolent disease are ongoing...
  34. ncbi request reprint Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:34-9. 2003
    ..To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma...
  35. ncbi request reprint Bone marrow angiogenesis in multiple myeloma: effect of therapy
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:665-71. 2002
    ..We conclude that the degree of bone marrow angiogenesis is a prognostic marker in patients with multiple myeloma and does not decrease significantly after therapy...
  36. pmc Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma
    Sumit Madan
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:232-8. 2010
    ..To identify and assess the clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma (MM)...
  37. ncbi request reprint Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study
    Rafael Fonseca
    Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:715-20. 2002
    ..03). The presence of Delta13 is an important and independent adverse prognostic factor in newly diagnosed MM and is associated with specific biological features...
  38. pmc Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 107:3384-8. 2006
    ..4, and 6.5 months, respectively. CMCs at the time of ASCT is an independent prognostic factor and in combination with cytogenetics provides a powerful scoring system that stratifies patients and guides management...
  39. ncbi request reprint Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
    Shaji Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:5668-74. 2005
    ..Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression...
  40. pmc The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
    Cheng E Chee
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 114:2617-8. 2009
    ..2 years vs 2.3 years, respectively; P = .01)...
  41. ncbi request reprint Fracture risk in monoclonal gammopathy of undetermined significance
    L Joseph Melton
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Bone Miner Res 19:25-30. 2004
    ..There was a 2.7-fold increase in the risk of axial fractures but no increase in limb fractures. The pathophysiologic basis for the increased axial fractures should be determined...
  42. ncbi request reprint Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Morie A Gertz
    Mayo Clinic, Rochester, MN, USA
    Semin Oncol 30:121-6. 2003
    ..11) Corticosteroids may be useful in the treatment of symptomatic mixed cryoglobulinemia. (12) Splenectomy is rarely indicated but has been used to manage painful splenomegaly and hypersplenism...
  43. ncbi request reprint Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
    Cynthia X Ma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 104:40-2. 2004
    ..In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk of subsequent evolution to MM. ESRD occurs late in the disease process...
  44. pmc Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma
    Alvin C Ng
    Division of Endocrinology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 84:397-400. 2009
    ..Am. J. Hematol. 2009. (c) 2009 Wiley-Liss, Inc...
  45. ncbi request reprint Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:1159-65. 2004
    ..The active inhibition of angiogenesis in MGUS is lost with progression, and the angiogenic switch from MGUS to NMM may involve a loss of inhibitory activity...
  46. ncbi request reprint Thalidomid: current role in the treatment of non-plasma cell malignancies
    Shaji Kumar
    Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 22:2477-88. 2004
    ..This article reviews the current status of thalidomide for the treatment of non-plasma-cell malignancies...
  47. ncbi request reprint Fracture risk with multiple myeloma: a population-based study
    L Joseph Melton
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Bone Miner Res 20:487-93. 2005
    ..Pathologic fractures, especially of the axial skeleton, are extremely common in patients with multiple myeloma and cluster around the time of diagnosis. Osteoporotic fractures seem to be less of a problem in these patients...
  48. pmc Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
    ....
  49. ncbi request reprint Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression
    Michael Kline
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:591-8. 2007
    ..We conclude that stromal cell IL-8 production parallels MM disease activity, is IL-1beta induced, and correlates with bone marrow angiogenesis...
  50. doi request reprint Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    R A Kyle
    Division of Hematology, Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1121-7. 2010
    ..Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months...
  51. pmc Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:799-802. 2009
    ..This approach warrants further investigation to confirm this and define the role of vaccine therapy in myeloma...
  52. doi request reprint Treatment of multiple myeloma: a comprehensive review
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 9:278-88. 2009
    ..The M-protein might lead to renal failure, hyperviscosity syndrome, or through the suppression of uninvolved immunoglobulins, recurrent infections. Anemia and hypercalcemia are common complications...
  53. ncbi request reprint Monoclonal gammopathies of undetermined significance: a review
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Immunol Rev 194:112-39. 2003
    ..MGUS may be associated with many different disorders, including lymphoproliferative diseases, leukemia, connective tissue disorders, dermatologic diseases, and neurologic disorders...
  54. doi request reprint Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 24:3132-7. 2009
    ..The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described...
  55. pmc Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
    Celine M Vachon
    Division of Epidemiology, Department of Health Sciences Research, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:785-90. 2009
    ..0; 95% CI, 1.4 to 2.8) and MGUS probands (RR, 3.3; 95% CI, 2.1 to 4.8). The increased risk of MGUS in first-degree relatives of MGUS or MM patients implies shared environment and/or genetics...
  56. pmc Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component
    John A Lust
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 84:114-22. 2009
    ..To conduct in vitro studies as well as a phase 2 clinical trial in patients with smoldering or indolent multiple myeloma to determine if interleukin 1 (IL-1) inhibitors can delay or prevent active myeloma...
  57. pmc Building a protocol expressway: the case of Mayo Clinic Cancer Center
    Terre A McJoynt
    Cancer Center Clinical Research Office, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 27:3855-60. 2009
    ..This results in dissatisfaction among sponsors, investigators, and staff and restricts the availability of novel treatment options for patients...
  58. pmc Multiple myeloma
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 111:2962-72. 2008
    ..We also provide an update on current concepts of diagnosis and therapy, with an emphasis on how treatments have emerged from a historical perspective after certain important discoveries and the results of experimental studies...
  59. pmc Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
    Angela Dispenzieri
    Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet 375:1721-8. 2010
    ..The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS...
  60. pmc Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:757-9. 2010
    ....
  61. ncbi request reprint Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy
    Deepak Kademani
    Division of Oral Diagnosis and Oral and Maxillofacial Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:1100-3. 2006
    ..We describe 2 patients in whom primary surgical salvage was performed successfully for ONJ. Our experience indicates that with appropriate technique, primary surgical treatment may offer benefit to selected patients with ONJ...
  62. ncbi request reprint Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 127:308-10. 2004
    ..The presence of an abnormal kappa/lambda FLC ratio in the serum was associated with a higher risk of MGUS progression (relative risk 2.5; 95% confidence interval: 1.6-4.0; P < 0.001)...
  63. ncbi request reprint The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Blood 109:465-70. 2007
    ..In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation...
  64. ncbi request reprint Helicobacter pylori infection and monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Divisions of Hematology, Gastroenterology and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:706-8. 2002
    ..pylori infection (33%) by serology, breath or stool testing between patients with MGUS and those with negative monoclonal protein studies. There was no evidence of resolution of MGUS with H. pylori therapy...
  65. pmc Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Minnesota, USA
    Am J Hematol 86:251-5. 2011
    ..It also highlights the importance of achieving at least a 90% reduction in the FLC-diff to improve the outcome of patients with light-chain AL...
  66. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011
    ..To examine whether the outcome of patients with primary systemic amyloidosis (AL) has improved over time and to identify predictors of early mortality in patients with AL...
  67. ncbi request reprint Review of 1027 patients with newly diagnosed multiple myeloma
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:21-33. 2003
    ..To determine the clinical and laboratory features of newly diagnosed multiple myeloma...
  68. pmc Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome
    Trista Stankowski-Drengler
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 85:431-4. 2010
    ..In summary, serum immunoglobulin profiles are unique in POEMS syndrome as compared with other plasma cell disorders...
  69. ncbi request reprint Proteasome inhibition as a novel therapeutic target in human cancer
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Oncol 23:630-9. 2005
    ..This article discusses proteasome inhibition as a novel therapeutic target in cancer and focuses on the development, mechanism of action, and current clinical experience with bortezomib...
  70. ncbi request reprint Influence of postoperative acute-phase response on angiogenesis and tumor growth: open vs. laparoscopic-assisted surgery in mice
    Miguel Pera
    Division of Colon and Rectal Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Gastrointest Surg 7:783-90. 2003
    ..67; P<0.001). We concluded that increased systemic levels of proinflammatory cytokines and VEGF are associated with increased angiogenesis and tumor growth after laparotomy compared to laparoscopy in mice...
  71. pmc Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
    Shaji Kumar
    Division of Hematology and Internal Medicine, Department of Laboratory Medicine and Pathology, Department of Biochemistry, Mayo Clinic, Rochester, MN, USA
    Blood 116:5126-9. 2010
    ..9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL...
  72. pmc Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
    Brian Van Ness
    Cancer Center, University of Minnesota, Minneapolis, MN, USA
    BMC Med 6:26. 2008
    ..To explore SNP associations with PFS we compared SNP profiles of short term (less than 1 year, n = 70) versus long term progression-free survivors (greater than 3 years, n = 73) in two phase III clinical trials...
  73. ncbi request reprint Identification of genes modulated in multiple myeloma using genetically identical twin samples
    Nikhil C Munshi
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston MA 02115, USA
    Blood 103:1799-806. 2004
    ..By identifying genes uniquely altered in MM cells compared with normal PCs in an identical genotypic background, the current study provides the framework to identify novel therapeutic targets...
  74. ncbi request reprint Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    Donna M Weber
    Department of Lymphoma and Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 357:2133-42. 2007
    ..Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma...
  75. ncbi request reprint Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 110:3557-60. 2007
    ..These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy...
  76. doi request reprint Clinical impact of discordance in serum albumin measurements on myeloma international staging system
    Prashant Kapoor
    J Clin Oncol 26:4051-2. 2008
  77. ncbi request reprint POEMS syndrome: definitions and long-term outcome
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:2496-506. 2003
    ..Additional features of the syndrome often develop, but the complications of classic multiple myeloma rarely develop...
  78. ncbi request reprint Allografting or autografting for myeloma
    S Vincent Rajkumar
    N Engl J Med 356:2646-8; author reply 2646-8. 2007
  79. pmc A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:3458-64. 2006
    ..Lenalidomide is active and well tolerated in relapsed, refractory myeloma, with the 30-mg once-daily regimen providing the basis for future studies as monotherapy and with dexamethasone...
  80. ncbi request reprint Thalidomide: tragic past and promising future
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:899-903. 2004
  81. ncbi request reprint Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Lymphoma 5:257-60. 2005
    ..It was concluded that the patients with IgM MGUS should be followed indefinitely...
  82. ncbi request reprint Genomic abnormalities in monoclonal gammopathy of undetermined significance
    Rafael Fonseca
    Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 100:1417-24. 2002
    ..Similar translocations are found in both MGUS and MM, including t(4;14)(p16.3;q32) and t(14;16)(q32;q23). Moreover, Delta 13 is common in MGUS and unlikely to play a predominant role in the evolution of MGUS to MM...
  83. ncbi request reprint Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
    James R Berenson
    Institute for Myeloma Bone Cancer Research, West Hollywood, California 90069, USA
    Cancer 104:2141-8. 2005
    ..Bortezomib, a first-in-class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma...
  84. ncbi request reprint Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana
    Ola Landgren
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Bldg EPS Room 7110, Bethesda, MD 20892 7236, USA
    Mayo Clin Proc 82:1468-73. 2007
    ....
  85. ncbi request reprint Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 104:1881-7. 2004
    ..Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT...
  86. doi request reprint Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 141:205-11. 2008
    ..Patients with pre-existing MGUS prior to myeloma diagnosis have a better outcome following HDT, reflecting more indolent disease and a favourable biology than those presenting with de novo myeloma...
  87. pmc Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 107:3378-83. 2006
    ..Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome...
  88. ncbi request reprint Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial
    Paul G Richardson
    Department of Medical Oncology Hematologic Malignancies, Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney Street, Boston, MA 02115, USA
    Cancer 106:1316-9. 2006
    ..Bortezomib, a first-in-class proteasome inhibitor, has shown clinical activity in relapsed, refractory multiple myeloma in a pivotal Phase II trial, SUMMIT...
  89. ncbi request reprint Prevalence of monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 354:1362-9. 2006
    ..We used sensitive laboratory techniques to ascertain the prevalence of MGUS in a large population in a well-defined geographic area...
  90. doi request reprint Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Heart Lung Transplant 27:823-9. 2008
    ..Historically, patients with AL amyloidosis and overt congestive heart failure have had an ominous prognosis with median survival of approximately 6 months...
  91. ncbi request reprint A phase 2 study of bortezomib in relapsed, refractory myeloma
    Paul G Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 348:2609-17. 2003
    ..Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity...
  92. ncbi request reprint Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:431-6. 2006
    ..To determine if thalidomide plus dexamethasone yields superior response rates compared with dexamethasone alone as induction therapy for newly diagnosed multiple myeloma...
  93. doi request reprint Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
    Shaji K Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:614-7. 2008
    ..The toxicity of transplant as well as the outcome appears comparable to younger patients. Patients with MM should not be excluded from HDT solely on the basis of their chronological age...
  94. ncbi request reprint Lenalidomide and venous thrombosis in multiple myeloma
    S Vincent Rajkumar
    N Engl J Med 354:2079-80. 2006
  95. ncbi request reprint Role of VAD in the initial treatment of multiple myeloma
    Steven W Lane
    Blood 106:3674; author reply 3674-5. 2005
  96. ncbi request reprint Monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 134:573-89. 2006
    ....
  97. ncbi request reprint Why not start with thalidomide?
    Charles Loprinzi
    Division of Medical Oncology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    J Clin Oncol 21:2211-4. 2003

Research Grants14

  1. Prevalence and Progression of Monoclonal Gammopathies
    S Rajkumar; Fiscal Year: 2007
    ..Families in which 3 or more first degree relatives are affected with MGUS are candidates for collaborative studies to look for genetic polymorphisms that predispose to MGUS. ..
  2. Treatment of Early Stage Multiple Myeloma
    S Rajkumar; Fiscal Year: 2006
    ..BM angiogenesis will be studied using immunostaining (IHC) for CD34 and an in vitro human angiogenesis assay. VEGF expression will be studied using IHC and quantitative RT-PCR. ..
  3. Angiogenesis and thalidomide therapy in multiple myeloma
    S Rajkumar; Fiscal Year: 2004
    ..This study offers a unique opportunity to serially study tumor cells and the tumor microenvironment following potential anti-angiogenic therapy. ..
  4. Prevalance and Progression of Monoclonal Gammopathies
    S Vincent Rajkumar; Fiscal Year: 2010
    ..We also study why (and how) some but not all people with MGUS progress to the fatal cancer called multiple myeloma. ..